In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Timoteo Delgado-Maldonado und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, Eugenol, Spike Glycoprotein, Coronavirus, Antiviral Agents. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional.
Abstract (Originalsprache)
Coronavirus Disease‐2019 (COVID‐19) caused by SARS‐CoV‐2 remains a serious health concern worldwide. Inhibitors of the protein–protein interaction (iPPI) between the SARS‐CoV‐2 spike protein (S) and human Angiotensin‐Converting Enzyme‐2 (ACE2) are promising as potential antiviral agents. This study aimed to identify and evaluate novel compounds as inhibitors of the S receptor‐binding domain (RBD) and ACE2 interaction through Eugenol‐ and Structure‐Based virtual screening approaches. The hit compounds were corroborated as protein–protein interaction inhibitors using an ELISA‐based enzyme assay. Molecular docking and molecular dynamics (MD) studies of the selected compounds showed that they maintained a molecular interaction and stability (RMSD fluctuations less than 4 Å) with essential residues of the S protein. The best compound, Eu‐1 (IC 50 = 16 μM), prevented the interaction between the S protein and ACE2 receptor efficiently with an 83.7% inhibition at 50 μM. In addition, Eu‐1 had an adequate value of cytotoxicity (CC 50 > 200 μM). Therefore, Eu‐1 is a candidate compound for further SARS‐CoV‐2 preclinical experiments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.
- Laboratorio de Estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de Ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Avenida Universidad S/N, Ex Hacienda Cinco Señore…
- Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, México.
- School of Integrative Biological and Chemical Sciences (SIBCS) & School of Earth, Environmental, and Marine Sciences (SEEMS), University of Texas Rio Grande Valley, Edinburg, Texas, USA.
ORCID-Profile: Timoteo Delgado-Maldonado, Alonzo González-González, Adriana Moreno-Rodríguez, Guadalupe Rojas-Verde, Alma D Paz-Gonzalez, Debasish Bandyopadhyay, Gildardo Rivera
Förderung
- Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional
Zitieren
APA
Delgado-Maldonado, T., González-González, A., Moreno-Rodríguez, A., Rojas-Verde, G., Paz-Gonzalez, A. D., Bandyopadhyay, D., & Rivera, G. (2025). In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70212
Vancouver
Delgado-Maldonado T, González-González A, Moreno-Rodríguez A, Rojas-Verde G, Paz-Gonzalez AD, Bandyopadhyay D, et al. In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70212
BibTeX
@article{DelgadoMaldonado2025,
author = {Delgado-Maldonado, Timoteo and González-González, Alonzo and Moreno-Rodríguez, Adriana and Rojas-Verde, Guadalupe and Paz-Gonzalez, Alma D and Bandyopadhyay, Debasish and Rivera, Gildardo},
title = {In Silico and In Vitro Identification of New Eugenol Derivatives as Inhibitors of the Spike SARS ‐ CoV ‐2 Protein Interaction With the ACE2 Host Receptor},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70212}
}
EUVIMED